Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Key facts
- Where
- Daejeon és Jeonju, Dél-KoreaSee the 2 sites
Where in Dél-Korea
- Chungnam National University HospitalDaejeon, Dél-KoreaTaking people
- jeonbuk National University HospitalJeonju, Dél-KoreaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Chungnam National University Hospital
- Trial code
- NCT06724653
- Record updated
- 2026. március 27.
- Original description
Study start date is on Nov 27th 2024.Read full original descriptionShow less
Study start date is on Nov 27th 2024.
A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
Inclusion: initial echocardiogram ejection fraction less than 40%; follow up echocardiogram ejection fraction over 50% and LVEDD index normal range; NTprobnp criteria; eGFR ≥60 ; less 440; eGFR 45-59: less 980; eGFR 30-44; less 1220; eGFR < 30 : less 5300; in HD; no criteria for NTproBNP; on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor).
Exclusion: significant valve disease; arrhythmia requiring rate control; under age 18 year; uncontrolled BP ( over 150/90); coronary revascularization within 6 months; CKD with albuminuria ( over 30mg/g); Pregnancy.